Crowds ooh'ed and ah'ed when the vehicle was unveiled, but today the high-tech police car prototype that Carbon Motors Corp. used to woo investors ��including government officials who awarded the company $7 million in public grants ��is all the bankrupt start-up has left.
STORY: Feds reject loan for police car maker Carbon Motors
STORY: Automakers' competition fierce for law-enforcement fleets
And now, it's going on the auction block.
The vehicle isn't likely to fetch anywhere near the amount state and local governments invested ��nor is it likely to put much of a dent in the $21.7 million the company owes private vendors and investors.
But that doesn't mean it wouldn't be a nice catch for a wealthy high-end car collector.
Top 10 Consumer Service Companies To Buy Right Now: Evolva Holding SA (EVE)
Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company�� nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company�� pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva�� compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class. Advisors' Opinion:- [By Glenwoods]
Earlier this year the giant food processor, Cargill, partnered with the small Swiss company, Evolva (SIX:EVE), which was developing its own stevia-based fermentation process, also in the pilot stage. As noted earlier in the article, Cargill is in a partnership with Coca-Cola for Truvia, the bestselling stevia product on the market. The success of the Cargill/Evolva partnership could have big implications not just for Cargill and Coca-Cola, but also on the entire stevia and sweetener market. I further believe the success of the partnership could have a major impact on Stevia First. If Cargill�� fermentation method produces a better tasting stevia product at a lower cost it would give Coca-Cola a considerable advantage over the other beverage bottlers, food manufacturers, and stevia producers. Such an outcome would force these companies to scramble to find a similar method in order to compete. There would be a very good chance that rival companies, in order to stay in the game, would have to turn to the other company developing a fermentation-based stevia product-- Stevia First. If that happens Stevia First�� value would rise considerably.
Hot Tech Companies To Buy For 2014: Velti plc(VELT)
Velti plc provides mobile marketing and advertising solutions for mobile operators, ad agencies, brands, and media groups. The company?s Mobile Marketing Platform (MMP) helps businesses to plan, execute, monitor, and measure mobile marketing or advertising campaigns on various digital delivery channels, including Internet sites, SMS and MMS, mobile TV, mobile communities, mobile applications, location-based services, and mobile social networking. Its MMP also helps in the creation of mobile Websites, portals, blogs, content, iPhone applications, branded games, and mobile widgets; and in the mobile marketing through mobile clubs, mobile content, contests, couponing, alerts and tips, photo/text to screen, green screen, and image remix applications. In addition, MMP offers Mobile CRM solutions that help in the creation and management of mobile communities, mobile broadcasts, member management, segment management, member rewards, multichannel registration, and advanced profil ing. It has operations in Europe, North America, the Middle East, and Asia. The company was founded in 2000 and is based in London, the United Kingdom.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 name that's quickly moving within range of triggering a big breakout trade is Velti (VELT), which provides mobile marketing and advertising technology solutions that enable brands, advertising agencies, and mobile operators to implement interactive and measurable campaigns by communicating with and engaging consumers via their mobile devices. This stock has been destroyed by the bears so far in 2013, with shares off sharply by 91%.
If you take a look at the chart for Velti, you'll notice that this stock recently gapped down big from over $1 a share to 33 cents per share with monster downside volume. Following that gap down, shares of VELT have started to consolidate and move sideways between 33 cents per share on the downside and 44 cents per share on the upside. Shares of VELT are spiking sharply higher on Thursday above some near-term support at 35 cents per share. That move is pushing this stock within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in VELT if it manages to break out above some near-term overhead resistance at 44 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 2.02 million shares. If that breakout triggers soon, then VELT could easily explode higher and potentially re-test its gap down day high from August at 66 cents per share.
Traders can look to buy VELT off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 35 cents to 33 cents per share. One can also buy VELT off strength once it clears 44 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Tech Companies To Buy For 2014: Sapient Corporation(SAPE)
Sapient Corporation helps clients to leverage marketing and technology to transform their businesses in the United States and internationally. It operates in three segments: SapientNitro, Sapient Global Markets, and Sapient Government Services. The SapientNitro segment offers Web and interactive development, traditional advertising, media planning and buying, strategic planning and marketing analytics, and multi-channel commerce strategy and solutions, including a focus on mobile, and content and asset management strategies and solutions. This segment also provides integrated marketing and creative services, such as visual concept, design, and implementation through multiple media; brand building and direct response programs, audience segmentation, and profiling strategies; customer loyalty strategies; customer relationship strategy and implementation; customer lead generation and management; and integrated advertising campaigns. The Sapient Global Markets segment offers i ntegrated advisory, program management, analytics, technology, and operations services to capital and commodity markets. This segment also provides business and information technology strategy, process and system design, program management, custom development and package implementation, systems integration, and outsourced services to financial services and energy services markets. The Sapient Government Services segment offers digital marketing strategy and execution, program management, solution delivery, strategy, and communications and outreach services, as well as provides consulting, technology, and marketing services to the United States governmental agencies and non-governmental organizations. The company serves financial services, technology and communications, consumer, travel, automotive, energy services, government, health, and education sectors. Sapient Corporation was founded in 1990 and is headquartered in Boston, Massachusetts.
Advisors' Opinion:- [By Jayson Derrick]
France-based Publicis Groupe (OTC: PUBGY) has agreed to acquire Sapient (NASDAQ: SAPE) for $3.7 billion, or $25 per share. Shares of Sapient surged to new 52-week highs of $24.73 before closing the day at $24.60, up 42.03 percent.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Sapient (Nasdaq: SAPE ) , whose recent revenue and earnings are plotted below. - [By CRWE]
Sapient (NASDAQ:SAPE) reportedthat Alan J. Herrick, president and chief executive officer, and Joseph S. Tibbetts, Jr., senior vice president and chief financial officer, will present at the Sanford C. Bernstein Strategic Decisions Conference at The Waldorf Astoria in New York on Thursday, May 31, 2012 from 4:00 p.m. to 4:45 p.m. ET.
Hot Tech Companies To Buy For 2014: Synergy Pharmaceuticals Inc (SGYP)
Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.
As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.
The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.
Advisors' Opinion:- [By Monica Gerson]
Breaking news
Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
No comments:
Post a Comment